RT Journal Article
SR Electronic
T1 Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 22
OP 25
DO 10.2967/jnmt.122.264904
VO 51
IS 1
A1 Emran Askari
A1 Soroush Zarehparvar Moghadam
A1 Damian Wild
A1 Ebrahim Delpassand
A1 Sergio Baldari
A1 Bernhard Nilica
A1 Philipp E. Hartrampf
A1 Grace Kong
A1 Chiara Maria Grana
A1 Martin Alexander Walter
A1 Francesca Capoccetti
A1 Pashtoon Murtaza Kasi
A1 Jonathan Strosberg
YR 2023
UL http://tech.snmjournals.org/content/51/1/22.abstract
AB Merkel cell carcinoma is a rare, aggressive skin malignancy, also known as neuroendocrine carcinoma of the skin, with high rates of recurrence and distant metastasis. In refractory metastatic Merkel cell carcinoma (mMCC), besides immunotherapy, chemotherapy, and radiation, peptide receptor radionuclide therapy (PRRT) may be a viable option since this type of tumor can express somatostatin receptors. Methods: We performed a comprehensive review of the literature to evaluate the efficacy of PRRT in mMCC patients. Results: Thirty-seven patients with mMCC received PRRT (1–5 cycles) with 177Lu- or 90Y-labeled somatostatin analogs (cumulative activity, 1.5–30 GBq). Radiographic response was available for 19 of 28 patients who received PRRT alone. Six (31.6%) of 19 patients showed objective responses, from partial to complete, and no severe adverse events were reported. Conclusion: Our analysis supports the use of PRRT in mMCC with sufficient somatostatin receptor uptake, although the quality of the available evidence is low. Prospective clinical trials are already in development and have started accruing in some parts of the world.